Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/31/08
End: 11/30/16
Due: 11/30/17
Phase: N/A
Priority: Normal
Start: 02/28/14
End: -
Due: -
Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides
Phase: N/A
Priority: Normal
Start: 01/31/17
End: 05/31/20
Due: 05/31/21
Phase: N/A
Priority: Normal
Start: 01/31/17
End: 06/30/18
Due: 06/30/19
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) | NCT00611208 | Angimmune LLC | user2@example.com | None | 2008-01-31 | 2016-11-30 | 2017-11-30 | - | - | 2025-07-14 |
| A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma | NCT01888081 | Angimmune LLC | user2@example.com | None | 2014-02-28 | - | - | - | - | 2025-07-14 |
| Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides | NCT02943642 | Angimmune LLC | user2@example.com | None | 2017-01-31 | 2020-05-31 | 2021-05-31 | - | - | 2025-07-14 |
| A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma | NCT02990416 | Angimmune LLC | user2@example.com | None | 2017-01-31 | 2018-06-30 | 2019-06-30 | - | - | 2025-07-14 |